Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Environmental Cues Control Reproductive Timing And Longevity, University Of Minnesota Study Shows
When humans and animals delay reproduction because food or other res are scarce, they may live longer to increase the impact of reproduction, according to a new study by University of Minnesota researchers published in the June 25 issue of PLoS (Public Library of Science) One.
generic viagra online
Lower Levels Of Key Protein Influence Tumor Growth In Mice, Stanford Study Shows
Tumors need a healthy supply of blood to grow and spread. Researchers at the Stanford University School of Medicine have identified a molecule that regulates blood vessel growth that is often found at less-than-normal levels in human tumors. Blocking the expression of the molecule, called PHD2, allows human cancer cells to grow more quickly when implanted into mice and increases the number of blood vessels feeding the tumor.
News of the day
Advocates Say Rise In Inquires About Adoption, Abortion Linked To Recession
Several large adoption agencies are reporting an increase in the number of women with unintended pregnancies who are considering adoption, a trend that some advocates say is tied to the recession, USA Today reports. Scott Mars of American Adoptions said that he has observed a 10% to 12% increase in the past year in the number of women asking about adoption and a 7% to 10% increase in actual placements. Mars said that the economy has led women to "take a second look at adoption." Adam Pertman of the Evan B. Donaldson Adoption Institute, a research group, said, "Finances are one of the major reasons women feel compelled to place their children for adoption." According to USA Today, more women also are considering delaying pregnancy or inquiring about abortion because of financial factors. A recent Gallup poll found that the economy has prompted one in 10 married women to delay pregnancy. Vicki Saporta of the National Abortion Federation, which represents abortion providers, said that calls to the group"s hotline have increased nearly threefold since 2008 and that many of the calls have come from women who have experienced job loss in their families.According to Joan Jaeger of the Chicago-area adoption agency The Cradle, about 30% more women are asking about placing a child for adoption than in 2008. She noted that many of the women inquiring about adoption are in their 20s and have at least one child. Joseph Sica of Adoption by Shepherd Care said he has seen a "dramatic increase in girls calling us from the hospital" who are interested in placing a child for adoption. Sica said that many of these women expect to receive assistance in raising their infants but inquire about adoption after they give birth and find that little help is available. He said that in 2008 his agency facilitated 14 such adoptions, an increase from 11 in 2007 and four in 2006. However, Chuck Johnson -- chief operating officer of the advocacy group the National Council for Adoption -- said that the percentage of women who place a child for adoption remains low overall, which he attributed to access to legal abortion and greater societal acceptance of single parenthood. Data from the National Center for Health Statistics show that before abortion became legal in 1973, one in five never-married white women and one in 10 never-married women overall placed a child for adoption after giving birth. Since then, that rate has "plummeted," USA Today reports. A 2002 survey, the most recent available, found that only 1% of such women placed a child for adoption (Koch, USA Today, 5/19).
Medical Devices

Achaogen Data Show Rapid Rise In Rates Of Resistance To Current Antibiotics

Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycoside (AG) resistance trends and comparative AG toxicities at the 19th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held May 16-19, 2009 in Helsinki, Finland. In three separate sessions, Achaogen and its research collaborators, including the Jones Microbiology Institute Laboratories in Iowa and Paul M. Tulkens, M.D. of the Universitç© catholique de Louvaine, Belgium, are highlighting study results that underscore the critical need for well-tolerated, next-generation AGs to combat multi-drug resistant Gram-negative pathogens and address a growing public health concern. AGs have been part of the clinical infectious disease armamentarium for roughly half a century; however, as the Achaogen and JMI Laboratories research shows, rates of bacterial resistance to existing AGs, including such widely used agents as gentamicin and amikacin, are far higher in all parts of the world than was expected, suggesting a need for a next-generation AGs that can treat these resistant pathogens. "The data being presented at ECCMID demonstrate that global resistance to AGs is increasing more rapidly than previously thought, and shows that resistance mechanisms of various Gram-negative pathogens are limiting the utility of other currently marketed antibiotics across most, and possibly all known drug classes," stated Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. "Bacteria are constantly evolving and becoming more resistant, and these findings reinforce the urgent need for new therapies to combat these varied mechanisms of resistance." Achaogen"s novel aminoglycoside agents-neoglycosides-have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multi-drug resistant Gram-negative organisms (including E. coli, K. Pneumoniae, P. aeruginosa, and Enterobacter spp.), as well as multi-drug resistant Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus (VRSA). They also overcome known aminoglycoside resistance mechanisms. Achaogen"s most advanced neoglycoside, ACHN-490, is being studied in a Phase 1 trial and initial clinical data are expected later this year. Overview of Findings "Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens" (Saturday, May 16); Poster # 636 The study assessed resistance trends to aminoglycosides over a ten-year period, using a global sample of Gram-negative pathogens. This study determined the resistance rates of commonly prescribed AGs (gentamicin, tobramycin, amikacin) against over 20,000 bacterial strains from nine Gram-negative bacterial species gathered from medical centers around the world. In particular, resistance to AGs from E. coli, the most common Gram-negative pathogen isolated in the study, increased in all geographic regions. Notably, in regions outside of North America, more than 50% of Acinetobacter spp. and more than 20% of P. aeruginosa isolates collected during 1998-2007 were resistant to gentamicin. The highest rates of AG resistance were observed in the Latin America and Asia-Pacific regions. The study results underscore the global issue of bacterial resistance to available AGs, and the value of developing new therapies, such as Achaogen"s neoglycosides, to treat multi-drug resistant Gram-negative infections. "Surveying aminoglycoside resistance mechanisms: a tool for the development of neoglycosides" (Saturday, May 16); Poster #643 Surveying AG resistance mechanisms among selected clinical isolates allows researchers to determine the spectrum of activity required of new compounds to overcome bacterial resistance to existing agents. In this study, multi-drug resistance was defined by resistance to three drug classes: aminoglycosides, fluoroquinolones and cephalosporins. The results demonstrate that while the overall prevalence of resistance to AGs is increasing, the distribution of AG-resistant mechanisms amongst AG-resistant isolates worldwide has remained stable during the past 20 years, suggesting that new agents that evade these mechanisms, such as neoglycosides, should remain useful for a long period of time against today"s AG-resistant bacteria. In addition, a poster entitled "Quantitative comparison of aminoglycosides nephrotoxicity in rats for effective screening and evaluation of new derivatives, and dosing rationales that minimize toxicity," Poster #1979, will be presented on Tuesday, May 19 at the ECCMID. This poster reviews data from a newly refined rat toxicity model that effectively quantifies the comparative nephrotoxicity of various aminoglycosides. This model allows for effective preclinical screening of Achaogen"s neoglycosides, and has informed the company"s selection of optimal dosing for clinical studies. About ACHN-490 Achaogen"s novel aminoglycoside agents-neoglycosides-overcome known aminoglycoside resistance mechanisms. Leveraging modern chemistry and biology, as well as the extensive scientific and clinical knowledge gained from decades of aminoglycoside usage, Achaogen is poised to enhance the prominence and utility of this important class of antibacterials against 21st-century pathogens. Achaogen"s lead neoglycoside, ACHN-490, has displayed efficacy in research and nonclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. The company initiated a Phase 1 clinical trial in early 2009 and data from this trial are expected in the second half of 2009. Achaogen


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009